U.S. FDA authorizes Novavax's COVID vaccine as booster for adults

The U.S. Food and Drug Administration on Wednesday authorized Novavax Inc's (NVAX.O) COVID-19 vaccine as a booster for adults, helping the company's shares reverse course and rise more than 3%. The authorization applies for people unable to get updated Omicron-tailored boosters, or those who would choose not to receive any other booster dose. The U.S. Centers for Disease Control and Prevention (CDC) will now have to recommend use of the vaccine as a booster.